Lademirsen
| Code | Size | Price |
|---|
| TAR-T38829-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Lademirsen (SAR339375; RG-012) is a highly specific antisense oligonucleotide (ASO) targeting miR-21 . Lademirsen has the potential for Alport nephropathy research.
CAS:
1404019-95-9
Formula:
0
Molecular Weight:
0
Purity:
0.98
SMILES:
0
References
Ivan G Gomez, et al. Anti-microRNA-21 oligonucleotides prevent Alport nephropathy progression by stimulating metabolic pathways. J Clin Invest. 2015 Jan;125(1):141-56.
Chiranjib Chakraborty, et al. Therapeutic advances of miRNAs: A preclinical and clinical update. J Adv Res. 2020 Aug 29;28:127-138.